Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
January 02 2024 - 8:30AM
Business Wire
Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a
company dedicated to discovering, developing, and deploying
promising health innovations, today announced that it has received
confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing
Panel that it has regained compliance with minimum stockholders’
equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to a
mandatory panel monitor until December 29, 2024.
This development is particularly significant in the context of
Aditxt's broader strategic goals. The Company is dedicated to
engaging stakeholders in accelerating innovation addressing
autoimmunity, health by the numbers, prolonging life through
transplantation, population health, and women's health with the
recently announced Evofem transaction. Regaining compliance with
Nasdaq's requirements paves the way for future growth and
innovation.
“Regaining compliance with Nasdaq is crucial for Aditxt,” Amro
Albanna, Co-Founder, Chairman, and CEO of Aditxt, commented on this
announcement. “It is a testament to our commitment to excellence in
corporate governance, operational integrity, and financial
transparency. Being publicly traded on the Nasdaq is integral to
our business model. It enables an inclusive approach to
decision-making, where stakeholders, not just a select few, can
actively participate in steering the course of promising
innovations. Today’s announcement validates our efforts and
reinforces our mission to advance health innovations that could
significantly impact global health outcomes and enhance shareholder
value.”
About Aditxt, Inc.
Aditxt is dedicated to discovering, developing, and deploying
promising health innovations. Aditxt’s diverse portfolio includes
Adimune™, Inc., developing a new class of therapeutics designed to
retrain the immune system to address organ rejection, autoimmunity,
and allergies; and Pearsanta™, Inc., offering timely, convenient,
and high-quality personalized lab testing anytime and anywhere,
backed by its CLIA-certified, CLEP, CAP-accredited monitoring
center.
For more information, visit Aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute on its strategic
M&A initiatives; the Company’s ability obtain the necessary
funding and partner to commence clinical trials; the Company’s
intellectual property position; the Company’s ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company’s results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102828707/en/
Media Relations Contact mobrien@aditxt.com Mary O’Brien
(516) 753-9933
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024